# Combination Treatment of NAs and Peg IFN α-2b for Hepatitis B Related, Compensatory Cirrhosis Patients

> **NCT03969017** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 84 (estimated)

## Conditions studied

- Cirrhosis of Liver Due to Hepatitis B (Disorder)

## Interventions

- **DRUG:** pegylated interferon (Peg IFN)α-2b
- **DRUG:** Nucleoside （acid）analogue (NAs)

## Key facts

- **NCT ID:** NCT03969017
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-17
- **Primary completion:** 2022-05-30
- **Final completion:** 2024-05-30
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2019-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03969017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03969017, "Combination Treatment of NAs and Peg IFN α-2b for Hepatitis B Related, Compensatory Cirrhosis Patients". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03969017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*